Nicotinic a4?2 receptors have been implicated in neurodegeneration and are being studied extensively. At University of California-Irvine (UCI), we have several major programs that would gain from imaging nicotinic receptors. These include: 1) Alzheimer's Disease Research Center (ADRC) at the institute for Mental Impairments and Neurological Disorders (MIND);2) Program on studies related to nicotine dependence;3) Program in the early detection of lung cancer, and 4) Neurobiology of learning and memory. During the previous funding period we have successfully completed preclinical evaluation of a new imaging agent, 18F-Nifene which has high affinity for a4?2 receptors and requires an imaging time of less than 60 minutes. In animal PET studies selective binding of 18F-Nifene in thalamus, lateral geniculate, cortex and other brain regions was observed with limited binding in the cerebellum, resulting in specific binding ratios of ~3. Plasma analysis indicated the presence of 18F-Nifene and no observed defluorination. The high ratios in specific brain regions and short scan time suggest that 18F-Nifene to be amongst the most suitable agonist that has good potential as a PET imaging agent for a4?2 receptors in humans. Our toxicity results of Nifene suggest that a radiotracer injection of 18F-Nifene is suitable for human use. Therefore, one goal in this NIH application is to carry out first human studies with 18F-Nifene. Human radiation dosimetry studies will be carried out using a PET/CT scanner on 6 subjects. Brain distribution of 18F-Nifene will be evaluated in normal volunteers in a test-retest paradigm to establish reproducibility and imaging methodology for quantitative analysis. A second goal of the proposal is to complete the preclinical development of 18F-Nifrolene which is a putative antagonist for this receptor. Animal studies show high binding in receptor-rich brain areas with a scan time of approx. 90 mins, with specific binding ratios ~4. We propose to complete animal imaging, toxicity testing and radiation dosimetry of 18F-Nifrolene during this funding period. The availability of an agonist and antagonist will allow comparative studies of this receptor system in various disorders. The third goal of this application is to evaluate if 18F-Nifene is able to detect changes in the level of the neurotransmitter, acetylcholine in PET studies. This will be of great value to evaluate efficacy of acetylcholinesterase inhibitors used in AD. The overall proposed research in this application will also support investigations in other disorders such as Parkinson's disease and schizophrenia.

Public Health Relevance

Development of human imaging methods for nicotine receptors will help understand several brain disorders, such as Alzheimer's disease, Parkinson's disease, learning and cognition as well as tobacco dependence and lung cancer. This grant application will specifically have implications in the potential diagnosis, treatment planning and therapeutics development for Alzheimer's disease.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Petanceska, Suzana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
Schools of Medicine
United States
Zip Code
Mukherjee, Jogeshwar; Lao, Patrick J; Betthauser, Tobey J et al. (2018) Human brain imaging of nicotinic acetylcholine ?4?2* receptors using [18 F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. J Comp Neurol 526:80-95
Samra, Gurleen K; Dang, Kenneth; Ho, Heather et al. (2018) Dual targeting agents for A? plaque/P-glycoprotein and A? plaque/nicotinic acetylcholine ?4?2* receptors-potential approaches to facilitate A? plaque removal in Alzheimer's disease brain. Med Chem Res 27:1634-1646
Samra, Gurleen K; Intskirveli, Irakli; Govind, Anitha P et al. (2017) Development of fluorescence imaging probes for nicotinic acetylcholine ?4?2? receptors. Bioorg Med Chem Lett :
Coleman, Robert A; Liang, Christopher; Patel, Rima et al. (2017) Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18F-FDG PET Imaging. Mol Imaging 16:1536012117704557
Betthauser, Tobey J; Hillmer, Ansel T; Lao, Patrick J et al. (2017) Human biodistribution and dosimetry of [18F]nifene, an ?4?2* nicotinic acetylcholine receptor PET tracer. Nucl Med Biol 55:7-11
Lao, Patrick J; Betthauser, Tobey J; Tudorascu, Dana L et al. (2017) [18 F]Nifene test-retest reproducibility in first-in-human imaging of ?4?2* nicotinic acetylcholine receptors. Synapse 71:
Pan, Min-Liang; Mukherjee, Meenakshi T; Patel, Himika H et al. (2016) Evaluation of [11C]TAZA for amyloid ? plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. Synapse 70:163-76
Pithia, Neema K; Liang, Christopher; Pan, Xiang-Zuo et al. (2016) Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors. Bioorg Med Chem Lett 26:1919-24
Mirbolooki, M Reza; Schade, Kimberly N; Constantinescu, Cristian C et al. (2015) Enhancement of 18F-fluorodeoxyglucose metabolism in rat brain frontal cortex using a ?3 adrenoceptor agonist. Synapse 69:96-8
Baranwal, Aparna; Mukherjee, Jogeshwar (2015) (18)F-Fluorodeoxyglucamines: Reductive amination of hydrophilic (18)F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents. Bioorg Med Chem Lett 25:2902-6

Showing the most recent 10 out of 24 publications